Europe Biopsy Devices Market Report by Product, Imaging Technology, End User, Country and Forecast 2026-2034

Europe Biopsy Devices Market Size & Forecast 2026-2034

The Europe Biopsy Devices Market is expected to grow steadily in the near future due to the rising rate of cancer and the increasing need for early diagnosis. The market is projected to grow from US$ 713.32 Million in 2025 to US$ 1206.16 Million in 2034 at a CAGR of 6.01% during the forecast period from 2026 to 2034. Development in healthcare infrastructure and the rising rate of preventive screening are also boosting the market for Biopsy Devices in Europe.

Europe Biopsy Devices Market Outlooks

Biopsy devices are medical tools used for obtaining small tissue or cell samples from the body for examination. The tissue obtained through biopsy devices is examined under a microscope to find unusual changes in the body. The biopsy devices available in the medical field include needle biopsy devices, vacuum-assisted biopsy systems, core biopsy needles, and biopsy forceps. These medical tools are used for conducting minimally invasive procedures to obtain accurate results with minimum discomfort and faster recovery for the patient. The biopsy method of obtaining medical results is commonly used for diagnosing diseases in organs like the breasts, lungs, prostate, liver, and skin.

Biopsy devices have gained popularity in Europe due to the increase in the number of people suffering from cancer and the importance of early detection of diseases. The governments of various countries in Europe have been promoting regular screening for disease detection to improve treatment results. Moreover, Europe boasts of advanced medical facilities, well-equipped hospitals, and medical professionals, which have made biopsy devices popular medical tools in the region. In addition, recent technological developments in biopsy tools have made the process accurate and safe for the patient, thereby popularizing these medical tools in Europe.

Growth Drivers of the Europe Biopsy Devices Market

Rising Prevalence of Cancer and Chronic Diseases

According to the European Cancer Information System, in 2022, there were 2.74 million new cancer cases reported. However, this figure is likely to rise to 3.24 million by 2040. The major cancer types include breast cancer, prostate cancer, lung cancer, and Colorectum cancer. These cancer types make up half of the total cancer cases reported. This increase in cancer is due to the aging population in Europe. People in older age groups are more prone to cancer. In 2022, 1.29 million cancer deaths were recorded. There were significant trends and differences in cancer deaths in Western Europe and Eastern Europe. One major factor that contributes to the growth of the Europe biopsy devices market is the rising cancer and chronic diseases. Cancer is one of the major causes of deaths in Europe. There is also a rise in the number of breast cancer, lung cancer, prostate cancer, and colorectal cancer. For effective treatment and high survival rates, cancer diagnosis is vital. Biopsy plays a major part in cancer diagnosis. Biopsy devices are used in the diagnosis process to obtain accurate results. Besides, the aging population of European countries has a high risk of developing chronic health conditions, which has created a higher need for diagnostic procedures such as biopsies. In addition, government-sponsored cancer screening programs and health awareness have contributed to the use of biopsy devices, thus boosting the market growth of the product. Therefore, the need for proper diagnostic tools has contributed significantly to the growth of the market for biopsy devices.

Technological Advancements in Minimally Invasive Biopsy Techniques

Technological innovations have been contributing to the growth of the biopsy devices market in Europe. Modern biopsy devices have been made to be minimally invasive. This ensures that medical practitioners can obtain tissue samples with greater precision and minimum discomfort to the patient. Image-guided biopsy devices, for instance, have been effective in ensuring accurate results and minimizing complications. Vacuum-assisted biopsy systems and biopsy needles have been effective in obtaining tissue samples in an efficient manner. Modern biopsy devices have been effective in ensuring better results for patients. This is due to the fact that biopsy devices have been made to be minimally invasive. As a result, patients have been able to obtain better results with minimum discomfort. Healthcare facilities in Europe have been using advanced biopsy technologies to obtain better results. Moreover, medical device manufacturers have been conducting constant research and development activities. This ensures the availability of better biopsy solutions. Oct 2025 - Olympus Corporation announces the launch of SecureFlex, a single-use fine needle biopsy device. SecureFlex will become commercially available in Europe and Japan in Autumn 2025.

Strong Healthcare Infrastructure and Government Screening Programs

The healthcare infrastructure in Europe is advanced, providing a boost to the use of advanced diagnostic equipment, such as biopsy equipment. In many European countries, the government offers healthcare services to the public, ensuring that people can seek early diagnosis and treatment for any disease. Many European countries have implemented cancer screening programs for breast, cervical, and colorectal cancer. This has created a greater demand for biopsy equipment to ensure early diagnosis. Many hospitals, diagnostic centers, and clinics are well-equipped with advanced medical diagnostic equipment, ensuring that healthcare professionals can use advanced biopsy equipment to ensure early diagnosis. In addition, the government has implemented initiatives to improve diagnostic equipment and preventive healthcare. Many people are also aware of the importance of preventive healthcare, and many people are opting for early diagnostic tests, thereby boosting the use of biopsy equipment. These factors are contributing to the growth of the biopsy equipment market in the region. February 2026, The EU4Health projects PRAISE-U, SOLACE & TOGAS have developed protocols and conducted pilots for these new cancer screening programmes across EU Member States.

Challenges of the Europe Biopsy Devices Market

High Cost of Advanced Biopsy Devices and Procedures

One of the key challenges faced by the Europe biopsy devices market is the high cost factor associated with the use of advanced biopsy technology and procedures. Advanced biopsy devices, especially those that are associated with image-guidance and vacuum-assisted techniques, require a high amount of investment, including the purchase of such equipment and the training of staff for the use of such devices. In the European market, the high cost factor associated with the use of advanced biopsy technology and procedures has the potential to impact the growth of the market, especially if the hospitals and other diagnostic centers are not able to afford the necessary expenditure for the purchase of such advanced devices. Although the European market has a government-supported healthcare system, the high cost factor associated with the use of advanced biopsy technology and procedures has the potential to impact the growth of the market.

Risk of Procedure-Related Complications and Patient Concerns

However, these biopsy procedures have some risks and associated complications, which may restrain the biopsy devices market. Some of the risks associated with biopsy procedures include pain, bleeding, and tissue damage in some patients. In addition, fear of biopsy procedures may restrain some people from undergoing biopsy procedures. This fear may arise due to the anxiety of experiencing pain and other associated complications during the biopsy procedure. In some cases, if the symptoms of the disease are not severe, people may avoid biopsy procedures. Moreover, some people may avoid biopsy procedures due to the misuse of biopsy equipment and the lack of trained professionals. Therefore, it is necessary to educate people and provide safe biopsy equipment to ensure the growth of the biopsy devices market in Europe.

Europe Needle-Based Biopsy Devices Market

The needle-based biopsy devices market in the region of Europe is expanding at a steady rate, primarily because of the rising demand for minimally invasive diagnostic procedures. Fine needle aspiration, as well as core needle biopsy, devices are mostly utilized for the detection of cancer and other diseases. Needle-based biopsies are preferred for diagnostic procedures, as they are minimally invasive, cost-effective, and provide faster recovery compared to surgical biopsy procedures. In the region of Europe, the incidence rate of breast, lung, and prostate cancer has increased to a significant level, thereby boosting the usage of needle-based biopsy devices. Healthcare professionals prefer the use of needle-based biopsy devices, as they are precise and provide accurate results. In addition, the design of the needles has been improvised, making the procedures safer and more efficient. Furthermore, the healthcare infrastructure, awareness, and screening for cancer in the region of Europe are contributing to the growth of the needle-based biopsy devices market.

Europe CT Scan Biopsy Market

The market for biopsy CT scans in Europe is growing, driven by an increase in the use of computed tomography scans to assist in biopsy operations. CT scans help healthcare professionals precisely locate areas in the body, such as the lungs, liver, abdomen, and other hard-to-reach areas, to collect samples through biopsy operations. This helps in improving the accuracy of the results, as well as minimizes the risks involved in the procedure. In Europe, an increase in the number of patients diagnosed with various diseases, such as cancer, is leading to an increase in the use of advanced diagnostic techniques to aid in the diagnosis of diseases. CT-guided biopsy operations are preferred over other methods, as they provide a precise targeting of the area, minimize the risks involved in the procedure, and help in improving the results of the operations. The availability of advanced healthcare facilities and professionals in Europe is helping to boost the market for CT-guided biopsy operations.

Europe MRI Guided Biopsy Devices Market

The market for MRI-guided biopsy devices in Europe has a high growth rate, driven by the rising need for highly accurate diagnostic procedures. MRI-guided biopsy enables the detailed visualization of soft tissue, which helps health professionals identify abnormalities that might not be visible through other means of imaging. This modality of diagnosis is also useful for the early detection of breast, prostate, and brain cancer. MRI-guided biopsy devices have high precision, minimizing the chances of incorrect diagnosis and treatment plans. European healthcare centers are increasingly adopting MRI-guided biopsy technology for the diagnosis of various health conditions, ensuring high precision and patient safety. In addition, the presence of high-end hospitals, rising investments in the healthcare sector, and the emphasis on the early detection of cancer have contributed significantly to the growth of the market for MRI-guided biopsy devices. Furthermore, the rising efficiency of MRI-guided biopsy technology has also contributed to the growth of the market for MRI-guided biopsy devices. In the future, the market for MRI-guided biopsy devices will grow steadily, driven by the rising need for accurate and minimally invasive diagnostic procedures.

Europe Biopsy Diagnostics Laboratories Devices Market

The European market for biopsy diagnostics laboratories devices is witnessing growth due to the increasing requirement for precise analysis of tissues collected during the procedure. Diagnostic laboratories utilize specialized equipment to investigate tissues collected during biopsies to detect diseases such as cancer, infections, and other health issues. An increase in the number of biopsies performed in Europe has led to a rise in the requirement for advanced laboratory diagnostic devices. These devices facilitate accurate diagnosis to ensure the formulation of appropriate treatment plans. Moreover, the development of advanced laboratory devices has also contributed to the growth of the European market for biopsy diagnostics laboratories devices. These developments have led to increased efficiency and accuracy in the diagnosis process. Europe has a well-developed healthcare system that supports the adoption of advanced devices used in the diagnosis process. Government initiatives to detect diseases at early stages have also contributed to the growth of this market segment.

Europe Biopsy Devices Hospital and Clinics Market

The biopsy devices market in Europe, particularly in hospitals and clinics, is growing due to the increasing number of diagnostic procedures carried out in these healthcare settings. Hospitals and clinics are the major settings for carrying out biopsy procedures, as these settings are equipped with advanced medical technologies and healthcare professionals. In recent years, the prevalence of cancer and other chronic health conditions has increased, leading to a greater need for diagnostic procedures. Biopsy devices are used to conduct these diagnostic procedures, and hospitals and clinics in Europe are investing in advanced medical equipment to conduct these procedures. In addition, the government is providing healthcare facilities to patients, and people are becoming more aware of the need to undergo diagnostic procedures to detect health conditions at an early stage. Clinics are also investing in diagnostic equipment, and this is making these settings more accessible to patients. In Europe, the presence of advanced healthcare infrastructure and skilled healthcare professionals is supporting the growth of the biopsy devices market in hospitals and clinics.

France Biopsy Devices Market

The French biopsy devices market is witnessing a steady growth rate due to the country’s well-established healthcare system and emphasis on early disease detection. In France, national cancer screening programs have been initiated, especially for breast, colorectal, and prostate cancer. This has led to an increase in the number of biopsy procedures. State-of-the-art medical equipment is installed in hospitals and diagnostic centers, ensuring efficient and precise biopsy procedures. In addition, the aging population in France is a major factor that has contributed to a higher incidence of chronic health conditions, thereby increasing the need for diagnostic equipment such as biopsy devices. Furthermore, the French government’s initiatives to promote preventive healthcare and regular health check-ups have led to an increased number of biopsy procedures. Technological innovations in minimally invasive biopsy devices have enhanced patient comfort and reduced recovery times. September 2023 – Roche France and the Institute Gustave Roussy, the leading cancer centre in Europe, today announced a groundbreaking partnership to develop in-house liquid biopsy testing at Institute Gustave Roussy’s sites in France, using Foundation Medicine’s FoundationOne Liquid CDx, a blood-based comprehensive genomic profiling (CGP) test.

United Kingdom Biopsy Devices Market

The market for biopsy devices is expanding in the UK with the support of the government for the healthcare industry and the increased adoption of advanced technologies for diagnosis. The National Health Service (NHS) is promoting the early detection of diseases like cancer through screening programs. As a result, the demand for biopsy procedures is on the rise. The increased incidence of diseases like cancer and other chronic diseases is requiring the need for accurate diagnosis. Advanced biopsy devices are being adopted for diagnosis. Additionally, the UK is witnessing increased investment in advanced biopsy equipment by hospitals and other diagnostic centers. Research and development activities are also contributing to the advancements in biopsy equipment. Public awareness campaigns on the importance of early diagnosis of diseases are motivating individuals to undergo regular health check-ups.  July 2025 - The unique Cambridge Prostate Biopsy Device, CamPROBE®, which was developed specifically for the performance of transperineal prostate biopsy procedures under local anaesthetic, is set to be made more widely available to hospitals and clinics throughout the UK with the announcement of a partnership between Medovate and J.E.B. Technologies and a newly appointed UK distributor, Aquilant.

Germany Biopsy Devices Market

The biopsy devices market in Germany is expanding at a steady rate due to its highly advanced medical system and focus on medical innovations. Germany boasts a large number of medical facilities, including hospitals and clinics, equipped with advanced biopsy technologies. The aging population in Germany contributes to an increase in the prevalence of cancer and other medical conditions. This results in an increase in the demand for accurate diagnostic procedures. In Germany, the medical facilities and institutions increasingly use minimally invasive biopsy devices for better patient comfort and accurate results. Additionally, Germany enjoys a strong reputation for medical device manufacturing. This ensures the availability of advanced biopsy technologies. Moreover, Germany provides its citizens with access to medical facilities through its government programs and health insurance. The country’s focus on investing in medical facilities and technological advancements contributes to the growth of the biopsy devices market.

Russia Biopsy Devices Market

The market for biopsy devices in Russia is growing, driven by the modernization of healthcare in Russia and the increasing demand for diagnostic services. The increasing rates of diseases, especially cancer and chronic conditions, have resulted in a significant need for early detection, thereby increasing the use of biopsy devices in Russia. The government of Russia is investing in improving healthcare in the country, including the modernization of hospitals and diagnostic centers to equip them with advanced medical devices. This is improving the availability of advanced biopsy techniques in major cities and healthcare centers in Russia. In addition, the awareness of the importance of early detection of diseases, coupled with the improvement in healthcare in Russia, is encouraging patients to seek diagnostic testing using biopsy devices. Although the availability of advanced healthcare devices in rural areas may differ from that in major cities, the improving healthcare in Russia is supporting the growing biopsy devices market in Russia. May 2025, OneCell, a joint venture of a company owned by the managing company of Azimut, a member of the Rostec State Corporation, has started the batch production of the first Russian microslide scanner, OneCell Scan 3.0, which enables the fastest and most precise cancer diagnosis.